Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2020

View Archived Issues

Sorrento develops Covidtrap protein for potential prevention and treatment COVID-19

BET on BD1 for cancer, BD2 for inflammation

Recruiting NK cells to the antitumor battle

AnHeart receives clinical trial authorization for taletrectinib in China

European Commission approves intravenous formulation of Akynzeo

FDA approves phase III study of Actemra in patients with severe COVID-19 pneumonia

First-in-human study of PLN-1474 for the treatment of liver fibrosis

Phase I data for influenza vaccination with a high-density microarray patch

Phase II data presented for intratumoral tavokinogene telseplasmid in metastatic melanoma

Researchers identify lncRNA RPL34-AS1 as potential therapeutic target in esophageal cancer

Arena Pharmaceuticals patents S1P1 agonists

Antibody gene therapy with AAV8-VRC07 appears feasible in HIV patients

Birdie Biopharmaceuticals discloses new imidazoquinoline derivatives

Pipeline Therapeutics identifies muscarinic M1 receptor antagonists

Achillion Pharmaceuticals presents complement factor D inhibitors

New eiF4E inhibitors presented by Pic Therapeutics

Biomedical R&D takes hit as university labs, trials shut down due to COVID-19

New MAb increases the effects of PF4 in sepsis, stabilizing NETs and enhancing microbial entrapment

AveXis releases new data from phase I/II study of intrathecal AVXS-101 in SMA type 2

Milestone reports phase III topline data on at-home use of etripamil for PSVT

Ascentage doses first U.S. patient in global study of APG-2575 for relapsed/refractory CLL/SLL

Synthon studies ADC SYD-1875 in first-in-human study for locally advanced or metastatic cancer

14,15-DHET is a marker of doxorubicin-related cardiotoxicity

USP28 regulates deltaNp63 protein abundance in squamous cell carcinoma and can be a druggable target

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...